Stephen M. Schleicher, MD, MBA, chief medical officer, Tennessee Oncology, previews the Nashville meeting of The American Journal of Managed Care®'s Institute for Value-Based Medicine® (IVBM), co-hosted by Tennessee Oncology.
Stephen M. Schleicher, MD, MBA, chief medical officer, Tennessee Oncology, previews the Nashville meeting of The American Journal of Managed Care®'s (AJMC®) Institute for Value-Based Medicine® (IVBM), co-hosted by Tennessee Oncology. At the event in Nashville, Tennessee, on April 21, 2022, experts will discuss advancing value-based cancer care.
Transcript
Who are you excited to see at the Nashville meeting of IVBM? What can attendees expect to learn from these speakers?
I'm very excited for this AJMC® IVBM conference in Nashville next Thursday, co-hosted by Tennessee Oncology. We have a great lineup of speakers and panelists, some focused on technology.
Bobby Green [MD] will be our first speaker. An oncologist, he was chief medical officer of Flatiron Health, now president at Thyme Care—a cancer navigation program that's just had a great fundraising seed from Andreessen Horowitz for their focus on helping patients navigate the entire cancer journey. Data and analytics is a big piece of that, to identify those patients that really need extra support from additional nurses, social workers, etc., to help with symptom management, keeping patients out of the hospital, a lot of the things that the Oncology Care Model taught us about as well, so that's going to be great.
We have Elaine Goodman, [MD, MBA] one of my close friends and colleagues from Brigham [and Women's Hospital] and Harvard Business School, who's one of the smartest people I know. She's done some great work with a company, Wellframe, which also helps with patient engagement. [She] now helps lead population health for the entire Mass General Brigham Women's Health System, as well as has spent time running the urgent care at Mass General Hospital. She's going to be phenomenal.
We have Ravi Parikh, [MD, MPP, FACP] also, who trained with me and Elaine at the Brigham, who does a lot of great work with provider engagement, helping early palliative care interventions. He's actually doing some work with Tennessee Oncology, which we're excited about, which we'll talk about. And then we have Hillary Cavanagh from [Center for Medicare & Medicaid Innovation], who's going to be able to speak to us about her takeaways from the Oncology Care Model. We're really excited that Hillary can join us.
And then a really exciting and unique panel of 3 of the top health care investment venture capitalists that I'm aware of. Ben Robbins [MD, MBA] from Google Ventures, who sat on the board of Aspire Health, a large cognitive care company that was bought by Anthem. We have Brenton Fargnoli, [MD, MBA] who also trained with me at Brigham in residency, who is at AlleyCorp [Healthcare Fund], who was a lead investor in Thyme Care. And Chris Booker, a good friend in Nashville at Frist Cressey, who has been involved with tons of health care innovation companies. Monogram [Health] is also a Frist Cressey investor to OneOncology.
So, a lot of exciting people to discuss what we've learned and where we're headed in the future. Technology is a piece of that but, in general, where's health care going to be in the next 5 years? How are we going to push towards innovation? I'm excited to hear what they can all offer. And Leah [Owens, DNP, RN, BMTCN, OCN], my co-host, and myself can't wait for the event.
Why are in-person meetings important for physicians as the country emerges from the pandemic?
In-person meetings are incredibly valuable to help us both learn in person from the speakers and panelists, but also at this conference, I can't wait for us all to learn from each other who are attending. It's going to be a great networking event. We have representative leaders from Tennessee Oncology, OneOncology, Ascension, Vanderbilt; we have even some Blue Cross there—our large commercial payer partner who has helped us build a medical home.
It's going to be great. We have over 100 people attending in-person and I can't wait for us to all be together and learn from our speakers and from each other at this event.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
Laundromats as a New Frontier in Community Health, Medicaid Outreach
May 29th 2025Lindsey Leininger, PhD, and Allister Chang, MPA, highlight the potential of laundromats as accessible, community-based settings to support Medicaid outreach, foster trust, and connect families with essential health and social services.
Listen
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial
June 6th 2025Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.
Read More
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More